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ABSTRACT
Introduction: There is significant intercentre variability
in access to renal transplantation in the UK due to
poorly understood factors. The overarching aims of
this study are to improve equity of access to kidney
and kidney–pancreas transplantation across the UK and
to optimise organ allocation to maximise the benefit
and cost-effectiveness of transplantation.
Methods and analysis: 6844 patients aged 18–
75 years starting dialysis and/or receiving a transplant
together with matched patients active on the transplant
list from all 72 UK renal units were recruited between
November 2011 and March 2013 and will be followed
for at least 3 years. The outcomes of interest include
patient survival, access to the transplant list, receipt of
a transplant, patient-reported outcome measures
(PROMs) including quality of life, treatment
satisfaction, well-being and health status on different
forms of renal replacement therapy. Sociodemographic
and clinical data were prospectively collected from case
notes and from interviews with patients and local
clinical teams. Qualitative process exploration with
clinical staff will help identify unit-specific factors that
influence access to renal transplantation. A health
economic analysis will explore costs and outcomes
associated with alternative approaches to organ
allocation. The study will deliver: (1) an understanding
of patient and unit-specific factors influencing access
to renal transplantation in the UK, informing potential
changes to practices and policies to optimise
outcomes and reduce intercentre variability; (2) a
patient-survival probability model to standardise access
to the renal transplant list and (3) an understanding of
PROMs and health economic impact of kidney and
kidney–pancreas transplantation to inform the
development of a more sophisticated and fairer organ
allocation algorithm.
Ethics and dissemination: The protocol has been
independently peer reviewed by National Institute for
Health Research (NIHR) and approved by the East of
England Research Ethics Committee. The results will
be published in peer-reviewed journals and presented
at conferences.
INTRODUCTION
Kidney transplantation is widely regarded to
be the best treatment for selected patients
with end-stage renal disease (ESRD). When
compared with dialysis, transplantation leads
to a twofold to threefold increase in life
expectancy and, it is often believed, a better
quality of life (QoL).1–4 Over the last decade,
transplant survival results have improved pro-
gressively and 1-year, 5-year and 10-year graft
survival rates are now >90%, >70% and
>60%, respectively. For selected patients with
ESRD due to type 1 diabetes, combined (or
simultaneous) pancreas and kidney (SPK)
transplantation offers a better life expectancy
compared with renal transplantation alone
(70% vs 30% at 10 years5 and ameliorates
diabetes complications).5 6
These successes have led to a greater
demand for transplantation with an ever
Strengths and limitations of this study
▪ First research programme involving all renal and
transplant units in the UK.
▪ An in-depth analysis (quantitative and qualitative) of
access to transplantation and transplant outcome.
▪ Correlation with patient-reported outcome mea-
sures, health status and quality of life.
▪ Health economic analysis exploring costs and
outcomes associated with alternative approaches
to organ allocation.
▪ Limitation due to recruitment process and
comorbidity data recorded at enrolment rather
than same time point for all study cohorts.
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increasing gap between supply and demand. The dem-
ography of patients with ESRD is also changing with an
ageing population having more comorbid conditions
that may preclude transplantation.7 8 Currently, fewer
than 40% of all patients with ESRD in the UK are listed
as suitable candidates for transplantation and only care-
fully selected patients, without severe cardiovascular
disease, undergo an SPK transplant. The need for
research on the impact of pretransplant comorbidity on
transplant outcome has been identiﬁed as a major prior-
ity in the UK by the Renal Association.9
It is important, in the interest of fairness and equity,
that access to the transplant waiting-list is, so far as is pos-
sible, standardised, transparent and based on validated
criteria. Recent evidence shows that access to transplant-
ation varies between and within the UK centres and dif-
ferences in assessment for comorbidity are likely to be a
major reason.10 However, even when the effects of
comorbidity are accounted for, there remains variation in
access to transplantation suggesting that other centre-
speciﬁc factors are implicated.11–13 It is unclear which
patient-speciﬁc and centre-speciﬁc factors are responsible
for such variations,11 14 or indeed which centre practices
represent the optimal approach. It is also unclear which
patient-speciﬁc and centre-speciﬁc factors impact on out-
comes following transplantation but the development of
a standardised approach would enable an evidence-based
decision-making at individual patient level.
Successful kidney transplantation appears to improve
QoL and health status compared with dialysis, but the
beneﬁt may not be apparent in all patient groups15–17
and is not supported by all studies.18 Furthermore, the
impact of kidney–pancreas transplantation on QoL has
not been conclusively established.19 There is a growing
body of evidence supporting the cost-effectiveness of
transplantation,20 21 but there are unresolved questions
about which patients may beneﬁt the most from trans-
plantation and how organ allocation can be further opti-
mised given scarce supply.
There is considerable interest in the development of
organ allocation schemes based on net transplant
beneﬁt and signiﬁcant work has already been under-
taken in the context of liver transplantation22 and car-
diothoracic transplantation23 in the UK and the USA.
However, existing kidney allocation policies don’t take
into account the potential impact of comorbid disease
on transplant outcome nor do they address the best use
of the increasing number of extended criteria deceased
donor organs.24–28 Recent research has quantiﬁed the
beneﬁt of kidney and SPK transplantation in order to
develop a survival probability model as a basis for listing
for transplantation (in the UK)29 or as a potential alloca-
tion model (in the USA).30 No work has yet been
carried out incorporating cost-effectiveness, health
status, QoL and other patient-reported outcome mea-
sures (PROMs) in any allocation algorithms.
In order to address some of these challenges in trans-
plantation, the UK National Institute for Health
Research (NIHR) Access to Transplantation and
Transplant Outcome Measures (ATTOM) research pro-
gramme has been developed by a consortium involving
all renal and transplant units in the UK. The overarch-
ing aims of the programme are to investigate how we
might maximise the net beneﬁt to society from kidney
and SPK transplantation, by selecting recipients in a
robust and transparent way so as to achieve the best
balance between cost, prolongation of life, QoL and
acceptability to patients and wider society. The ﬁve
related research aims of the study are listed below.
1. To identify patient-speciﬁc and centre-speciﬁc factors
that inﬂuence (a) access to the transplant waiting-list
and to develop a survival probability model as a basis
for standardising access to the transplant waiting-list
and (b) access to transplantation (deceased donor
kidney and pancreas and living donor kidney) for
wait-listed patients.
2. To identify patient-speciﬁc and centre-speciﬁc factors
that inﬂuence patient survival for transplant wait-
listed dialysis patients, after deceased donor kidney
transplantation, after SPK transplantation, after living
donor kidney transplantation and after pre-emptive
transplantation (transplantation as a ﬁrst mode of
renal replacement therapy (RRT) prior to the initi-
ation of dialysis treatment).
3. To evaluate QoL and other PROMs for patients on
dialysis, after deceased donor kidney transplantation,
after SPK transplantation, after living donor kidney
transplantation, after pre-emptive transplantation, in
waiting-list controls for kidney and SPK transplant-
ation and in those whose transplants have failed fol-
lowing recruitment to ATTOM.
4. To perform a health economic analysis to explore
costs and outcomes associated with alternative
approaches to organ allocation.
5. To utilise survival, health status, QoL, treatment satis-
faction and costs to determine an optimal organ allo-
cation policy as deﬁned by the maximisation of
clinical and cost–beneﬁts derived from
transplantation.
We describe the study population and the method-
ology underpinning the study analyses.
METHODS AND ANALYSIS
Study population
All 72 renal units (of which 23 are renal transplant
units) in the UK contributed to the ATTOM pro-
gramme. Between 1 November 2011 and 31 March
2013, 6360 patients aged 18–75 years were recruited in
three cohorts: incident dialysis patients, incident kidney
and SPK transplant patients and prevalent listed patients
selected as controls for transplanted patients (ﬁgure 1).
A total of 484 patients moved cohorts (13 patients
moved twice) resulting in 6844 registrations within
ATTOM (ﬁgure 2). In each centre, recruitment took
place over a 1-year period aiming to include every
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patient <75 years of age starting RRT. Controls were
selected automatically from the UK Transplant Registry
database on a fortnightly basis and were matched for:
age (within 5 years), time on the list, pre-emptive/on
dialysis and the type of transplant (deceased donor or
living donor).
Patient-level data (see online supplementary
appendix 1) were collected prospectively at the time of
starting dialysis, at the time of transplantation or when
identiﬁed as a control from the transplant list.
Dedicated research nurses collected clinical and
demographic information from the case notes and local
electronic databases, and collected health status and
well-being data from patients via completion of the
EuroQoL ﬁve dimensions (EQ-5D)31 and 12-item
Well-being Questionnaire (W-BQ12).32–35 The data were
uploaded onto a secure website designed, developed
and maintained by the UK Renal Registry (UKRR). Data
completeness for the items recorded is illustrated in
ﬁgure 3A, B. Data collection accuracy was ensured using
uniform deﬁnitions and a training process for the
research nurses. An independent data validation of
coding of 5% of case notes in all research sites con-
ﬁrmed >98% concordance for all coded ﬁelds.
The demographic characteristics of the three study
cohorts are illustrated in table 1.
Analysis
Access to transplantation
Patient-level and centre-level factors inﬂuencing access to
transplantation for patients starting dialysis are identiﬁed
through quantitative and qualitative analysis. Patients are
followed up for 4 years with data provided by the UKRR/
Scottish Renal Registry and the UK Transplant Registry at
National Health Service Blood and Transplant (NHSBT)
in order to identify whether they are wait-listed for trans-
plant or not, and if wait-listed, whether they received a
transplant or not (ﬁgure 4). This will inform the analysis
of the factors inﬂuencing access to listing after starting
dialysis and subsequent transplantation.
The qualitative analysis aims to identify systems and
processes consistently associated with better (or worse)
outcomes in units across the UK, to help deﬁne best
practice in transplant work-up and listing. This work-
stream consists of 40 initial qualitative interviews with
key stakeholders and patients in a sample of 9 units
stratiﬁed by proportion of listed dialysis patients,
whether transplant or dialysis centre and geography to
include spread of deprivation and ethnicity of the catch-
ment area. This is followed by a purpose-designed struc-
tured questionnaire for use in a survey of all the UK
renal and transplant units. A Delphi consensus study will
provide better understanding of professional views on
what characterises patients who should (and should not)
be assessed for transplant listing and how they should be
assessed. The Delphi study, undertaken by emailed elec-
tronic questionnaire with two rounds includes transplant
surgeons and nephrologists from each centre.
Participants are asked to agree or disagree with a series
of statements about the eligibility criteria for listing. The
initial overall responses are fed back and participants
invited to reconsider their views in this second round
prior to summarising ﬁnal levels of agreement. Finally,
both patient-level and centre-level factors (from the
survey) are explored to determine their inﬂuence on
transplant listing and subsequent access to
transplantation.
Survival with transplantation versus dialysis
Using data derived from the access to transplantation
analysis, a multivariate Cox proportional hazards model
will estimate the potential risk factors for mortality while
on dialysis and their associated HRs, taking into account
patient-level and centre-level factors in a multilevel mod-
elling approach. Changes over time in the impact of
factors measured at baseline on outcome are modelled
using time-varying coefﬁcients. Interactions between
variables (eg, age and comorbidity) are included in the
ﬁnal model if signiﬁcant. This will allow the develop-
ment of a survival probability prediction tool, which can
inform nationally agreed thresholds (such as ‘predicted
survival >80% at 2 years after start of dialysis’) at which a
patient should be activated and deactivated on the trans-
plant list. The survival probability tool could be incorpo-
rated on a desktop or web-based platform enabling
Figure 2 Number of patients changing between the study
cohorts and the direction of change.
Figure 1 ATTOM, Access to Transplantation and Transplant
Outcome Measures (ATTOM) study patient recruitment and
cohort distribution.
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clinicians to discuss risk versus beneﬁts with patients
when considering transplant listing. A nationally agreed
survival probability threshold will also enable robust
intercentre comparison to audit listing practices.
Follow-up of the dialysis cohort in conjunction with the
cohorts illustrated in ﬁgure 5, beyond the 5-year dur-
ation of this project will enable further reﬁnement of
the survival probability assessment tool including the
option to predict quality-adjusted life years gained with
transplantation.
The study cohorts enable the analysis of patient-
speciﬁc factors that inﬂuence survival for listed patients,
after kidney transplantation (live and deceased donors)
or after SPK transplantation. A multilevel modelling
approach is used to analyse transplantation outcome
data and the modelling explores how the outcome vari-
ables depend on one or more of the explanatory factors
(patient and centre level). The models are developed
on the basis of manual variable selection based on clin-
ical and statistical input and are built up by repeatedly
incorporating the most statistically signiﬁcant variable
and retesting all others in the presence of included vari-
ables, using clinical input to ensure development of a
clinically appropriate model. Clinically relevant interac-
tions between variables are predetermined and consid-
ered in the model building.
Figure 3 (A and B) Data completeness for each item collected in the study.
4 Oniscu GC, et al. BMJ Open 2016;6:e010377. doi:10.1136/bmjopen-2015-010377
Open Access
Evaluation of PROMs
All patients in the ATTOM programme were asked by
the research nurses to complete measures of health
status (using the EQ-5D and W-BQ12) at or soon after
recruitment and at 6 months in those transplanted
patients and matched controls on the waiting-list for
transplant who were recruited during the ﬁrst 6 months
of nurse data collection. The EQ-5D provides an overall
measure of perceived health ‘today’ and ﬁve individual
items measuring mobility, pain, self-care, usual activities
and anxiety/depression.31 The W-BQ12 has subscales to
measure negative well-being (including depressed and
anxious mood), energy and positive well-being over the
past few weeks and an overall measure of general well-
being.32–35 In addition, a detailed PROMs study on a
subset of 652 ATTOM patients (table 2) recruited in a
quasi-random manner (the ﬁrst eligible patient for each
group seen each month by each nurse) is evaluating
QoL and the impact of the renal condition on QoL.
This uses the individualised Renal-Dependent QoL
(RDQoL) measure36 together with the Audit of
Diabetes-Dependent QoL (ADDQoL) for people who
also have diabetes37 38 or a version of the ADDQoL with
minor adaptations for people receiving an SPK trans-
plant. These questionnaires are administered at 3 and
12 months post-transplant and at comparable times for
those on dialysis. The Renal Treatment Satisfaction
Questionnaire status (RTSQs) version39 is given along-
side the RDQoL at each time point, and the Diabetes
Treatment Satisfaction Questionnaire status
(DTSQs40 41) version is given to all those with diabetes
(with minor adaptations for those who have received an
SPK transplant). In addition, change versions of the
RTSQ and DTSQ (the RTSQc and DTSQc)42–44 are
given at 12 months to provide a direct comparison
between satisfaction with current treatment and satisfac-
tion with the treatment used before the study began.
The EQ-5D and W-BQ12 are also included with the
12-month questionnaires in the detailed PROMs
cohorts. The target patient groups and the timing of
each questionnaire are summarised in table 3.
Transplant recipients completed baseline questionnaires
before transplantation where possible (patients receiving
pre-emptive transplants) and within a few weeks of
Table 1 Demographic characteristics of the study cohorts
Incident dialysis Incident transplant Matched controls
N 2623 2262 1959
Age at registration to ATTOM
Mean±SD 56.18±13.55 49.34±13.44 50.38±12.83
Median (IQR) 58.39 (47.48–67.14) 50.28 (40.07–59.89) 51.14 (41.67–60.34)
Gender (%)
Male 64.93 62.81 57.91
Female 35.07 37.19 42.09
Ethnicity (%)
White 79.95 82.45 74.54
Asian 11.23 9.40 12.42
Black 7.09 6.21 10.93
Chinese 0.69 0.75 0.92
Mixed 0.65 0.80 0.87
Not specified 0.38 0.40 0.31
Age first seen by nephrologist
Mean±SD 50.14±15.66 39.85±15.36 39.38±15.41
Median (IQR) 52.76 (39.85–62.68) 40.59 (28.65–51.61) 39.91 (28.24–51.48)
ATTOM, Access to Transplantation and Transplant Outcome Measures.
Figure 4 Quantitative and qualitative analysis approach for access to transplantation workstream.
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transplantation (deceased donor transplants). Patients
were given the option to complete the questionnaires via
telephone interviews or using mailed paper
questionnaires.
Demographic and clinical data are used by the health
psychologists alongside QoL and PROMs using multi-
level modelling techniques in investigating the factors
determining QoL measured by the RDQoL and health
status measured by the EQ-5D and exploring the rela-
tionship between these two outcomes.
Sixty of the detailed PROMs patients (including
patients from each treatment group purposively sampled
to include those reporting above and below the mean
for their treatment group on RDQoL scores) are
included in a qualitative interview study to elicit further
information about their experiences, with particular
interest in variations in QoL, reasons for satisfaction or
dissatisfaction with treatment and their understanding
and views about the current and future possible organ
allocation schemes.
Health economic analysis
The proposed health economic analysis focuses on the
development of a model to simulate different
approaches for allocating deceased donor kidneys to
patients on the transplant waiting-list. Rather than
attempting to identify one optimal allocation scheme,
the analysis explores a range of conceptual schemes that
reﬂect varying levels of emphasis on the principles of
equity and efﬁciency. Each allocation scheme is evalu-
ated in terms of cost and health outcomes captured by
estimating quality-adjusted life years (QALYs).
The model is developed as a discrete event simulation
(DES). This approach offers the ﬂexibility to incorpor-
ate the inﬂuence of patient-level characteristics, such as
age and comorbidities, in the estimation of both costs
and health gains, to model competing risks and to
capture the dynamic consequences of the allocation
process for all patients subject to a constrained supply of
donor organs.45 The model is populated using various
sources of data with costs of RRT from NHS reference
costs and variable hospital costs drawn on patient-level
resource use from Hospital Episodes Statistics (HES).
Survival for patients on the waiting-list and following
transplant is estimated by ﬁtting predictive models to his-
torical data from NHSBT, while health state utility esti-
mates are based on EQ-5D data prospectively collected
in the ATTOM study.
Novel allocation schemes
An important outcome of ATTOM is to propose alterna-
tive organ allocation policies that consider efﬁciency
and equity factors as well as QoL gains from transplant-
ation utilising data on survival, health status, QoL and
ﬁnancial costs.
Under the current UK allocation scheme, kidneys are
allocated according to an algorithm that among other
variables favours those who have waited longest and have
a better tissue-type match to the donated organ. Apart
from avoiding extreme age mismatches, no account is
taken of other more complex indicators such as the
‘quality’ of the kidney, patient QoL and cost-
effectiveness of different types of transplant (such as
donation after brain death (DBD) or donation after cir-
culatory death (DCD) transplants). Furthermore, no
attempt is made to pair estimated graft life with esti-
mated recipient survival. In several countries, there is
now great interest in developing organ allocation
schemes based on transplant beneﬁt, while the USA has
introduced an allocation procedure taking into account
the estimated post-transplant survival and the donor
kidney quality (as measured by the kidney donor proﬁle
index).30
The principles of organ allocation procedures based
on net beneﬁt involve the calculation of scores that
reﬂect the potential beneﬁt of transplantation based on
comprehensive outcome analyses, an individual’s life
expectancy with and without a given transplant and to
prioritise patients who have most to gain. At a point
Figure 5 Study cohorts for survival analysis comparison.
Table 2 Detailed PROMs study group
Subgroup
Number
of patients
Incident dialysis patients 147
Kidney transplant waiting-list patients 135
SPK transplant waiting-list 29
Deceased donor kidney transplant recipients 120
Living donor kidney transplant recipients 104
SPK transplant recipients 103
Failed transplant 14
PROMs, patient-reported outcome measures; SPK, simultaneous
pancreas and kidney.
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when a donor organ becomes available, the expected
number of days of life without a transplant can be com-
pared with the expected number of days of life following
receipt of a transplant. This procedure requires the
development of statistical models for survival following
wait listing and for survival post-transplantation.
On the basis of the information obtained in the
study, we will also explore deceased donor kidney allo-
cation (including kidneys from DCD donors) on the
basis of a continuous index of donor organ longevity,
along with a continuous index of potential transplant
recipients that predicts their likely survival when trans-
planted over that on dialysis (ie, life years gained due
to transplantation). We will incorporate information
on QoL into the allocation model by assigning scores
for transplantation with different types of organs (ie,
DCD or DBD) versus dialysis, informed by the PROMs
workstream. Similarly, the cost-effectiveness of trans-
plantation with different types of donor organs could
be explored in the model. These data will then be
assessed alongside other factors that predict length of
wait and survival enabling the development of model
(s) which predict an accurate difference in the overall
net beneﬁt of a particular type of transplant, thus
maximising organ utilisation and the overall beneﬁt
for the patients. The impact of potential models of
organ allocation will be tested using simulations where
the properties of different schemes can be explored
and compared, and the impact of policy changes can
be forecast. Allocation schemes that focus on different
aspects, such as maximum beneﬁt from an organ or
equal access to transplantation, can be simulated and
the results used to help identify an allocation scheme
that provides a balance between efﬁciency and equity
that is acceptable to patients and society.
ETHICS AND DISSEMINATION
Renal transplantation is one of the most successful ther-
apies in modern medicine. However, the landscape of
renal transplantation has changed signiﬁcantly over the
last decade with an increasing need, in an older popula-
tion with more comorbidities and a different donor
population, with a higher number of extended criteria
donors and DCD. As a consequence, there are a
number of major challenges currently facing the provi-
sion of renal transplant services. Some of these chal-
lenges raise ethical concerns regarding the transparency
of the selection process, the consistency of the decision-
making process and the equity of access to the trans-
plantation. These issues are at the core of ATTOM and
the involvement of patients and ethicists throughout the
design and conduct of the study are key to the success
of this programme.
Comorbidity, particularly cardiovascular comorbidity,
is common in patients with chronic kidney disease
(CKD) and may be an important factor leading to
inequity in access to transplantation.10 Previous studies
have demonstrated that demographic variables such as
gender, age, geographical location and level of social
deprivation inﬂuence access to transplantation10 14 46–49
and their interpretation varies signiﬁcantly between
Table 3 Tools for QoL and other PROMs analysis, target population and timing of administration
Tool
Time of
administration Patient cohort
EuroQoL five dimensions (EQ-5D) health status tool Recruitment
6 months
1 year*
All cohorts
Those in first 6 months of data collection for
transplant and matched control patients
Patients in detailed PROMs cohort
Well-Being Questionnaire (W-BQ12) Recruitment
6 months
1 year*
All cohorts
Those in first 6 months of data collection for
transplant and matched control patients
Patients in detailed PROMs cohort
Renal-Dependent Quality of Life (RDQoL)
Questionnaire
3 months*
1 year*
Patients in detailed PROMs cohort
Renal Treatment Satisfaction Questionnaire—status
version (RTSQs)
3 months*
1 year*
Patients in detailed PROMs cohort
Renal Treatment Satisfaction Questionnaire—
change version (RTSQc)
1 year* Patients in detailed PROMs cohort
Audit of Diabetes-Dependent Quality of Life
(ADDQoL) Questionnaire†
3 months*
1 year*
Patients in detailed PROMs cohort who have
diabetes
Diabetes Treatment Satisfaction Questionnaire—
status version (DTSQs)†
3 months*
1 year*
Patients in detailed PROMs cohort who have
diabetes
Diabetes Treatment Satisfaction Questionnaire—
change version (DTSQc)†
1 year* Patients in detailed PROMs cohort who have
diabetes
*Detailed PROMs cohort only.
†Modified versions of these questionnaires were completed by recipients of deceased donor SPK transplants.
PROMs, patient-reported outcome measures; QoL, quality of life; SPK, simultaneous pancreas and kidney.
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centres, raising further concerns about an equal chance
of consideration for transplantation. Unlike previous
reports, which are retrospective or based on registry ana-
lyses, ATTOM is collecting prospective comorbidity data
at the time of patients starting dialysis and assesses its
impact according to the outcome as shown in ﬁgure 4.
Furthermore, the planned analyses will enable us to
assess further potential inequities in access to transplant-
ation after listing and establish the impact of comorbid-
ity and sociodemographic variables on the outcome of
renal transplantation, SPK transplantation and dialysis.
The study design and the data collected in ATTOM
allow individual patient predictions to be generated,
facilitating more informed decision-making. Importantly,
it will provide uniformly applicable and explicit
evidence-based assessment criteria for entry onto the
national transplant waiting-list for kidney and SPK trans-
plantation addressing some of the major ethical con-
cerns highlighted above.
Combining a quantitative and qualitative analysis is
one of the novel aspects of ATTOM, allowing an
in-depth analysis of individual centre practices, policies
and beliefs as well as the views held by patients. By iden-
tifying the recipient and organisational factors that most
inﬂuence access to transplantation and subsequent
transplant outcome, the ﬁndings will address key ethical
concerns and indicate where clinical practice can be
changed or reﬁned to achieve fairer and more transpar-
ent access to transplantation.
The impact of comorbidity on SPK transplantation
outcomes is also unclear, particularly given the more
stringent selection criteria for this procedure.50 There is
an ongoing debate regarding the survival beneﬁt of SPK
transplantation over and above renal transplantation
alone, particularly living donor renal transplantation.
ATTOM addresses this issue by directly comparing out-
comes in patients taking account of differences in socio-
demographics and comorbidity.
There is a strong perception that successful kidney
transplantation improves health-related QoL compared
with dialysis. One of the ATTOM workstreams addresses
these issues providing information on quality of health,
QoL, well-being and treatment satisfaction using a com-
bination of established generic instruments as well as
recently developed condition-speciﬁc measurement tools
designed for people with CKD. Furthermore, the study
may identify which particular subgroups of patients are
likely to gain most or least from transplant because of
comorbid disease.
ATTOM includes a health economic analysis that pro-
vides insight into long-term cost and survival differences
associated with dialysis and transplantation. While the
effectiveness of transplantation has already been estab-
lished, ATTOM considers current clinical pathways and
enables further exploration of the impact of donor and
recipient factors on both costs and outcomes in the
modelling of alternative approaches to allocating organs
in the UK.
Organ allocation schemes (addressed in workstream
5) and issues such as which patients should receive pri-
ority, which organs should be used and which criteria
should inform the allocation decision are at the heart of
ethical debates in transplantation.
Data from this study will be curated by the NHSBT
and UK Registry providing an ethical reassurance
regarding the use of the information collected in the
study.
The results of ATTOM will be of direct relevance to
patients and their clinicians, and are expected to
reshape the provision of renal transplantation in the UK
by evaluating the entire CKD pathway from dialysis to
transplantation. From a public perspective, ATTOM will
provide unprecedented transparency in the decision-
making with regard to the use of a scarce national
resource. Therefore, we plan to disseminate these ﬁnd-
ings widely in peer-reviewed journals, at national and
international conferences and thorough public engage-
ment days. Furthermore, we intend to engage all rele-
vant stakeholders in the discussions concerning any
proposed alternative organ allocation schemes.
In conclusion, ATTOM is the ﬁrst research pro-
gramme involving all renal dialysis and renal transplant
units in the UK that explores in depth the relationship
between access to transplantation and transplant out-
comes. The outputs of the study are likely to have a sig-
niﬁcant impact on the delivery of renal transplantation
in the UK.
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